Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

Recruiting

Phase 2

ABBV-932 with AntidepressantsStudy to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

Sponsor:

AbbVie

Code:

NCT06846320

Conditions

Generalized Anxiety Disorder (GAD)

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

ABBV-932

Placebo for ABBV-932

Antidepressant Therapy (ADT)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-01-21. This information was provided to ClinicalTrials.gov by AbbVie on 2026-01-16.